| Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre … R Stupp, ME Hegi, T Gorlia, SC Erridge, J Perry, YK Hong, KD Aldape, ... The lancet oncology 15 (10), 1100-1108, 2014 | 1038 | 2014 |
| Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a … U Herrlinger, T Tzaridis, F Mack, JP Steinbach, U Schlegel, M Sabel, ... The lancet 393 (10172), 678-688, 2019 | 489 | 2019 |
| NFKBIA Deletion in Glioblastomas M Bredel, DM Scholtens, AK Yadav, AA Alvarez, JJ Renfrow, JP Chandler, ... New England Journal of Medicine 364 (7), 627-637, 2011 | 297 | 2011 |
| Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection F Ringel, SN1 study group, H Pape, SN1 Study Group, M Sabel, ... Neuro-oncology 18 (1), 96-104, 2015 | 243 | 2015 |
| Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The … U Herrlinger, N Schäfer, JP Steinbach, A Weyerbrock, P Hau, ... Journal of Clinical Oncology 34 (14), 1611-1619, 2016 | 196 | 2016 |
| Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma A Scholz, PN Harter, S Cremer, BH Yalcin, S Gurnik, M Yamaji, ... EMBO molecular medicine 8 (1), 39-57, 2016 | 163 | 2016 |
| Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation … W Wick, T Gorlia, P Bady, M Platten, MJ Van Den Bent, MJB Taphoorn, ... Clinical cancer research 22 (19), 4797-4806, 2016 | 146 | 2016 |
| Residual tumor volume as best outcome predictor in low grade glioma–a nine-years near-randomized survey of surgery vs. biopsy R Roelz, D Strohmaier, R Jabbarli, R Kraeutle, K Egger, VA Coenen, ... Scientific reports 6 (1), 32286, 2016 | 146 | 2016 |
| Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas F Fack, H Espedal, O Keunen, A Golebiewska, N Obad, PN Harter, ... Acta neuropathologica 129, 115-131, 2015 | 144 | 2015 |
| Chloroquine or chloroquine-PI3K/Akt pathway inhibitor combinations strongly promote γ-irradiation-induced cell death in primary stem-like glioma cells E Firat, A Weyerbrock, S Gaedicke, AL Grosu, G Niedermann Public Library of Science 7 (10), e47357, 2012 | 114 | 2012 |
| Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the … K Draaisma, A Chatzipli, M Taphoorn, M Kerkhof, A Weyerbrock, ... Journal of Clinical Oncology 38 (1), 81-99, 2020 | 111 | 2020 |
| TERT promoter mutations and telomere length in adult malignant gliomas and recurrences B Heidenreich, PS Rachakonda, I Hosen, F Volz, K Hemminki, ... Oncotarget 6 (12), 10617, 2015 | 108 | 2015 |
| Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression R Ferrarese, GR Harsh, AK Yadav, E Bug, D Maticzka, W Reichardt, ... The Journal of clinical investigation 124 (7), 2861-2876, 2014 | 102 | 2014 |
| Comprehensive analysis of PD-L1 expression in glioblastoma multiforme DH Heiland, G Haaker, D Delev, B Mercas, W Masalha, S Heynckes, ... Oncotarget 8 (26), 42214, 2017 | 99 | 2017 |
| Whole brain irradiation with hippocampal sparing and dose escalation on multiple brain metastases: Local tumour control and survival. O Oehlke, D Wucherpfennig, F Fels, L Frings, K Egger, A Weyerbrock, ... Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft …, 2015 | 95 | 2015 |
| Tumor vessel normalization, immunostimulatory reprogramming, and improved survival in glioblastoma with combined inhibition of PD-1, angiopoietin-2, and VEGF M Di Tacchio, J Macas, J Weissenberger, K Sommer, O Bähr, ... Cancer immunology research 7 (12), 1910-1927, 2019 | 90 | 2019 |
| European Organisation for Research and Treatment of Cancer (EORTC); Canadian Brain Tumor Consortium; CENTRIC study team. Cilengitide combined with standard treatment for … R Stupp, ME Hegi, T Gorlia, SC Erridge, J Perry, YK Hong, KD Aldape, ... Lancet Oncol 15 (10), 1100-1108, 2014 | 89 | 2014 |
| Cytokine Production during Sleep and Wakef ulness and Its Relationship to Cortisol in Healthy Humans F Hohagen, J Timmer, A Weyerbrock, R Fritsch-Montero, U Ganter, ... Neuropsychobiology 28 (1-2), 9-16, 1993 | 79 | 1993 |
| Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA)–protocol of a randomized phase II trial (NOA 10/ARO 2013-1) O Oehlke, M Mix, E Graf, T Schimek-Jasch, U Nestle, I Götz, ... BMC cancer 16, 1-10, 2016 | 75 | 2016 |
| Incidence and outcome of aneurysmal subarachnoid hemorrhage: the Swiss Study on Subarachnoid Hemorrhage (Swiss SOS) B Schatlo, C Fung, MN Stienen, AR Fathi, J Fandino, NR Smoll, ... Stroke 52 (1), 344-347, 2021 | 74 | 2021 |
